DNA vaccine for preventing toxoplasmosis of humans or animals

Abstract

The invention discloses a DNA vaccine for preventing toxoplasmosis of humans or animals. An ROP19 gene is amplified through PCR, the amplified ROP19 gene is inserted into a eukaryotic expression vector pEGFP-C1 to build recombinant plasmid pEGFP-C1-ROP19 (pROP19), the recombinant plasmid containing a target gene is extracted, and the toxoplasma gondii ROP19DNA vaccine is obtained. According to the DNA vaccine for preventing the toxoplasmosis of the humans or the animals, active immunization is conducted on BALB / c mice through the DNA vaccine, the immunogenicity of the vaccine is evaluated by determining cells and humoral immunity indexes of immunized mice, and the immunoprotectivity of the vaccine is estimated by counting the number of cysts in brains of the mice and the survival rate of the mice after attack experiments of toxoplasma gondii are conducted. By means of the DNA vaccine for preventing the toxoplasmosis of the humans or the animals, humoral immunity and cellular immune responses can be effectively enhanced, the formation rate of the brain cysts of the immune mice attacked by a toxoplasma gondii PRU strain (II type) is effectively decreased, and the survival time of the mice attacked by a toxoplasma gondii RH stain (I type) is prolonged.

Description

technical field [0001] The present invention relates to a vaccine, in particular to a compound antigenic epitope based on toxoplasma gondii rod protein 19 (ROP19), a toxoplasma vaccine obtained by constructing a recombinant plasmid containing a target gene, used for human or animal toxoplasmosis prevention. Background technique [0002] Toxoplasma gondii (Toxoplasmagondii) is a worldwide distribution of parasitic protozoa, widely parasitic in nucleated cells of humans and animals, causing severe zoonotic diseases. Toxoplasma infection in early pregnancy women can lead to miscarriage, premature birth or even stillbirth, and can also cause neonatal malformations and fetal eye complications through the placenta. Toxoplasma gondii can lead to severe clinical symptoms (such as toxoplasmic encephalopathy) and even death for people with weak or weak immunity (such as AIDS and tumor patients). In immunocompetent hosts, Toxoplasma tends to form chronic infections, causing irreversi...

AI Technical Summary

Problems solved by technology

There have been some reports on the vaccine research of ROP family members, mainly including ROP1 and ROP2 families. The ROP2 family members that have been confirmed as vaccine candidate genes include ROP2, ROP4, ROP5, ROP8, ROP13, ROP16, ROP17 and ROP18. The amino acid sequences and specific structural units of the rod-shaped proteins are different, resulting in different immune principles and different immune protection effects.

[0004] The article "Immuneresponse induced by recombinant Mycobacterium bovis BCG expressing ROP2 gene of Toxoplasmagondii" published in the SCI journal Parasitology International publicly reported the research report on ROP2 DNA vaccine, but the immune protection effect of ROP2 DNA vaccine was not satisfactory

In addition, the vaccines prepared from other ROP proteins mentioned above do not have the excellent performance of simultaneously resisting RH strain Toxoplasma gondii (type I strain) and PRU strain toxoplasma gondii (type II strain)

[0005] The ROP19 protein, one of the members of the ROP family, is mainly located in the rods and vacuoles of Toxoplasma gondii. At present, there are few research reports on ROP, and there is no correlation of ROP19 protein in the preparation of DNA vaccines for the prevention of human or animal toxoplasmosis. to report

Images